The cannabis industry entered 2026 with renewed optimism following recent developments in U.S. federal rescheduling. However, the latest quarterly results from major cannabis companies show a market still grappling with slowing growth, margin pressure, operational challenges, and investor skepticism. At the same time, international expansion, medical cannabis demand, and improving operational efficiency continue to create long-term opportunities.
Recent financial updates from Organigram Global Inc., Canopy Growth, and WM Technology provide a useful snapshot of where the cannabis sector stands midway through fiscal 2026.
The Industry Is Still Growing, But Growth Is Uneven
One of the clearest takeaways from recent earnings reports is that cannabis demand has not disappeared. However, growth is becoming increasingly selective by geography, product category, and business model.
Organigram remains one of the strongest operators in Canada by market share, holding leading positions in vapes, milled flower, and concentrates. The company also continues to push aggressively into international markets.
Its acquisition of Germany-based Sanity Group could become one of the more important cannabis deals of 2026. Organigram expects Sanity Group to generate roughly €25 million in average quarterly revenue over the next year while helping accelerate expansion across Europe.
Europe is increasingly becoming one of the most attractive long-term cannabis growth stories. Germany’s medical cannabis market has expanded rapidly since legalization reforms, and many Canadian operators are positioning themselves to benefit from future EU demand.
Organigram also launched cannabis products in Australia, including vapes and gummies, and is expected to reach more than 4,000 pharmacies.
These international moves suggest that cannabis companies are no longer relying solely on Canadian recreational sales to drive growth. Investors have spent years criticizing the Canadian market for oversupply, price compression, and weak profitability. Companies with exposure to medical and international markets may now have a clearer path toward sustainable expansion.
Still, growth remains inconsistent.
Organigram’s Q2 revenue fell 9% year-over-year to $59.8 million, while adjusted EBITDA dropped 82% to just $0.9 million. The company blamed weaker vape sales, production issues with infused pre-rolls, slower industry growth, and increased product returns.
Profitability Remains a Major Challenge
Even companies reporting strong operational progress are still posting thin margins, cash burn, or declining earnings.
Organigram’s results showed pressure across several key financial metrics, despite operational improvements such as record yields and higher THC potency. Gross margins narrowed, SG&A expenses increased, and the company posted a net loss for the quarter.
Meanwhile, Weedmaps owner WM Technology reported softer revenue and declining adjusted EBITDA as cannabis operators cut advertising spending amid difficult market conditions.
Revenue at WM Technology fell from $44.6 million to $43.6 million year-over-year, while adjusted EBITDA dropped from $10.1 million to $5.9 million.
The company also reported fewer paying clients, highlighting ongoing stress among dispensaries and cannabis retailers.
Ancillary cannabis businesses like Weedmaps are often viewed as indicators of broader industry health. When operators reduce marketing budgets, it usually suggests margin compression and slower consumer spending across the supply chain.
The cannabis sector is clearly no longer in hypergrowth mode.
Canopy Growth’s Accounting Issue Adds More Uncertainty
One of the more concerning developments came from Canopy Growth, which announced plans to restate financial results for multiple fiscal years after identifying a technical accounting error involving U.S.-dollar-denominated warrants.
The company emphasized that the issue is non-cash and does not affect revenue, operating income, adjusted EBITDA, liquidity, or overall business performance.
Still, the announcement adds another layer of uncertainty to a company that has already endured years of restructuring, heavy losses, and investor frustration.
Canopy also applied for a management cease trade order affecting certain directors and officers, pending completion of the refiling process.
That said, Canopy stressed that the restatement should not change the company’s core financial narrative or operational trajectory.
Federal Reform Continues to Shape Investor Sentiment
Despite operational challenges, federal cannabis reform remains one of the industry’s biggest long-term catalysts.
WM Technology specifically referenced recent U.S. cannabis rescheduling developments as a “meaningful federal step forward.”
Even though the full impact of rescheduling may take years to materialize, investors continue to view federal reform as a major potential turning point for cannabis stocks.
If cannabis moves into a less restrictive federal classification in the U.S., the industry could eventually benefit from:
- Easier access to banking and institutional capital
- Lower tax burdens under IRS 280E reforms
- Greater M&A activity
- Improved exchange listing opportunities
- Expanded medical research
- More normalized interstate commerce discussions
However, investors should also remember that policy momentum does not automatically translate into immediate financial improvement.
The current earnings season shows that, even with improving sentiment around reform, cannabis companies still face operational execution risks and a difficult competitive environment.
Rita Ferreira
Rita is a seasoned writer with over five years of experience, having worked with globally renowned platforms, including Forbes and Miister CBD. Her deep knowledge of hemp-related businesses and passion for delivering accurate and concise information distinguish her in the industry. Rita's contributions empower individuals and companies to navigate the complexities of the cannabis world, and her work remains a valuable resource for those seeking a deeper understanding of its potential.
